MustGrow Biologics Corp. (TSXV:MGRO)
Canada · Delayed Price · Currency is CAD | Market Cap | 28.18M -31.6% |
| Revenue (ttm) | 9.51M +1,237.8% |
| Net Income | -5.57M |
| EPS | -0.09 |
| Shares Out | 70.44M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,275 |
| Open | 0.4000 |
| Previous Close | 0.3850 |
| Day's Range | 0.4000 - 0.4000 |
| 52-Week Range | 0.2900 - 0.9400 |
| Beta | 0.57 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 25, 2026 |
About MustGrow Biologics
MustGrow Biologics Corp., an agricultural biotechnology company, focuses on development and commercialization of natural biological technologies and products from mustard plants. The company provides Biocontrol technology platform to treat soil-borne diseases and pests for various crops, including fruit, vegetables, and others; treat unwanted plant growth for use in organic agriculture, and home and garden markets, as well as agriculture markets where glyphosate has been banned; and suppress sprouting, and treat disease and pathogen for storage... [Read more]
Financial Performance
In 2025, MustGrow Biologics's revenue was 8.29 million, an increase of 1981.95% compared to the previous year's 398,018. Losses were -7.26 million, 48.5% more than in 2024.
Financial StatementsNews
MustGrow Biologics Transcript: 20th International Investment Forum (IIF)
TerraSante sales reached ~CAD 875,000 by Aug. 15, 2026, up 46% vs. 2025, while production constraints continue to limit supply. Bayer’s registration program for TerraMG has reached its first milestone payment, and broader commercialization depends on regulatory approvals and capacity expansion.
MustGrow targets $380B agriculture market with field-proven, mustard-based biologicals
Colin Bletsky, COO & Director of MustGrow Biologics Corp. discusses how firm turns naturally occurring compounds in to products that help farmers improve yield.
MustGrow Announces Officer Appointment and Grant of DSUs
Saskatoon, Saskatchewan--(Newsfile Corp. - September 4, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") today announced the appointment of Tyler R...
MustGrow Biologics Slides: Corporate presentation
MustGrow Biologics has posted slides in relation to its latest quarterly earnings report, which was published on September 1, 2026.
MustGrow Biologics Earnings Call Transcript: Q2 2026
Q2 2026 saw TerraSante sales rise 46% year-over-year, with strong demand in strawberries and potatoes, but gross margins were pressured by costly air freight. Manufacturing improvements and a shift to ocean freight are expected to restore margins and support positive cash flow in 2027.
MustGrow Biologics Report: Q2 2026
MustGrow Biologics published a report on August 31, 2026 containing material business information for investors and shareholders.
MustGrow Biologics MD&A: Q2 2026
MustGrow Biologics filed a regulatory document on August 31, 2026 disclosing important business information.
MustGrow Biologics Earnings release: Q2 2026
MustGrow Biologics released its Q2 2026 earnings on August 31, 2026, summarizing the period's financial results.
MustGrow Announces Second Quarter 2026 Financial Results
Investor Webcast: Monday, August 31 st at 4:00pm ET / 1:00pm PT Register/View Here: https://us02web.zoom.us/webinar/register/1317861230560/WN_oKTSGbCQR1KjX5MnyGC3kw#/registration Please join/register ...
Market One: MustGrow Biologics Receives First Bayer Milestone Payment
Vancouver, British Columbia--(Newsfile Corp. - August 24, 2026) - Market One ("Market One"), a marketing agency for public companies, shares editorial and video features on emerging growth stories acr...
First Bayer milestone payment received for mustard-based biocontrol
Colin Bletsky, Chief Operating Officer of MustGrow Biologics Corp., discusses the biotech innovator's focus on replacing synthetic soil fumigants with mustard seed-derived biocontrol.
MustGrow Receives First Milestone Payment from Bayer AG
Bayer AG has paid MustGrow the first development milestone payment. The MustGrow / Bayer AG License and Collaboration Agreement, signed in December 2023, covers soil applications of MustGrow's mustard...
MustGrow Biologics Corp. Announces Results of Shareholder Meeting
Saskatoon, Saskatchewan--(Newsfile Corp. - June 26, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), is pleased to announce the results of its 202...
MustGrow Closes $3.7 Million Non-Brokered LIFE Offering
Saskatoon, Saskatchewan--(Newsfile Corp. - June 19, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), is pleased to announce the closing of its pre...
MustGrow Increases Non-Brokered LIFE Offering to Approximately $3.7 Million
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Saskatoon, Saskatchewan--(Newsfile Corp. - June 17, 2026) - MustGrow Biologics Corp. (TSXV...
MustGrow Biologics Slides: Corporate presentation
MustGrow Biologics has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
MustGrow Biologics Earnings Call Transcript: Q1 2026
Q1 2026 saw the first TerraSante sales, improved margins, and a narrowed focus after discontinuing NexusBioAg. Manufacturing issues limited Q1 growth, but demand is strong and management expects a stronger second half, with international expansion and capital raises supporting growth.
MustGrow Biologics Earnings release: Q1 2026
MustGrow Biologics released its Q1 2026 earnings on May 29, 2026, summarizing the period's financial results.
MustGrow Biologics Report: Q1 2026
MustGrow Biologics published a report on May 29, 2026 containing material business information for investors and shareholders.
MustGrow Biologics MD&A: Q1 2026
MustGrow Biologics filed a regulatory document on May 29, 2026 disclosing important business information.
MustGrow Announces First Quarter 2026 Financial Results
Investor Webcast: Friday, May 29 th at 4:00pm ET / 1:00pm PT Register/View Here: https://us02web.zoom.us/webinar/register/7717781882447/WN_m6cQAgeQSD6hjP6JeVpfbw Please join/register at least 5 minute...
MustGrow Announces Non-Brokered LIFE Offering of Approximately $2 Million
Saskatoon, Saskatchewan--(Newsfile Corp. - May 25, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") is pleased to announce a non-brokered private p...
MustGrow Receives Texas, Utah, and Montana Registrations for TerraSante(TM) Biofertility Product
MustGrow has received approval from the agriculture departments of Texas, Utah, and Montana to commence sales of organic biofertility product TerraSante TM . Based on infield grower data, the mustard-...
MustGrow Announces Market Awareness Services and Investor Relations Agreements
Saskatoon, Saskatchewan--(Newsfile Corp. - May 14, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") announces the following market awareness servic...
MustGrow Biologics Earnings Call Transcript: Q4 2025
2025 sales fell short due to NexusBioAg underperformance, but TerraSante sales surged 377% year-over-year. Focus is now on expanding TerraSante in the U.S. and globally, with improved margins expected in 2026 and cash flow breakeven targeted for 2027.